Semaglutide for Type 2 Diabetes (2 mg)

Abstract

For patients with type 2 diabetes mellitus, a single randomized controlled trial (SUSTAIN FORTE) suggested that once-weekly subcutaneous semaglutide 2.0 mg may achieve better glycemic control than once-weekly subcutaneous semaglutide 1.0 mg. However, it is unclear whether between-group differences are clinically meaningful. Gastrointestinal disorders were the most common adverse event resulting in premature discontinuation in both groups. One participant in each study arm experienced a cardiovascular disorder serious enough for premature discontinuation. As most trial patients were white, it is unclear if the results are generalizable to groups with higher prevalence of T2DM in Canada, such as Indigenous peoples or those of South Asian descent. We did not find any studies on the cost-effectiveness of subcutaneous semaglutide 2.0 mg, compared to placebo or other doses of semaglutide.